• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Introduction to 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine (CAS No. 91271-79-3)

1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine, identified by its Chemical Abstracts Service number CAS No. 91271-79-3, is a significant compound in the field of pharmaceutical chemistry. This compound belongs to a class of molecules that exhibit promising biological activities, making it a subject of extensive research and development. The unique structural features of 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine contribute to its potential applications in drug discovery and therapeutic interventions.

The molecular structure of this compound consists of a phenyl ring substituted with a pyrrolidine moiety, which is further connected to a methylamino group. This configuration imparts specific chemical and pharmacological properties that make it an attractive candidate for medicinal chemistry studies. The presence of the pyrrolidin-1-yl group is particularly noteworthy, as it is known to enhance the solubility and bioavailability of pharmaceutical agents, thereby facilitating their absorption and distribution within biological systems.

In recent years, there has been growing interest in the development of novel compounds that incorporate heterocyclic structures, such as pyrrolidine, due to their ability to modulate various biological pathways. Research has demonstrated that molecules containing the pyrrolidin-1-yl moiety often exhibit inhibitory effects on enzymes and receptors involved in inflammation, pain, and neurodegenerative diseases. This has spurred investigations into the potential therapeutic applications of derivatives like 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine.

The phenyl ring in the structure of 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine serves as a scaffold that can be modified to optimize pharmacokinetic properties and target specificity. The methylamino group at the terminal position further enhances the compound's reactivity, allowing for further functionalization through various synthetic methodologies. These features make it a versatile building block for designing new drugs with tailored biological activities.

Recent studies have highlighted the importance of understanding the structural determinants that influence the biological activity of small molecules. Computational modeling and experimental techniques have been employed to elucidate the interactions between 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine and biological targets. These studies have provided valuable insights into how modifications to the core structure can enhance binding affinity and selectivity, which are critical factors in drug design.

The pharmaceutical industry has shown particular interest in compounds that exhibit dual or multi-target interactions, as this approach can lead to more effective therapeutic outcomes with fewer side effects. The unique combination of functional groups in 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine positions it as a promising candidate for such strategies. By targeting multiple pathways simultaneously, this compound could potentially address complex diseases more comprehensively.

In addition to its pharmacological potential, 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine has also been explored for its role in chemical synthesis. Its structural complexity allows for diverse modifications, making it a valuable intermediate in the preparation of more complex molecules. Researchers have leveraged its reactivity to develop novel synthetic routes that could be applied to other areas of organic chemistry.

The synthesis of 1-{4-[(pyrrolidin-1-yl)methyl]phenyl}methanamine involves multi-step reactions that require careful optimization to ensure high yield and purity. Advances in synthetic methodologies have enabled more efficient production processes, which are essential for scaling up compounds for industrial applications. Techniques such as catalytic hydrogenation and palladium-catalyzed cross-coupling reactions have been particularly useful in constructing the desired molecular framework.

The safety and efficacy of any pharmaceutical compound must be rigorously evaluated before it can be considered for clinical use. Preclinical studies have been conducted on derivatives of 1-{4-[pyrrolidin-1-ylmethyl]phenyl}methanamine to assess their biological activity and potential toxicities. These studies have provided preliminary evidence supporting its suitability for further development into therapeutic agents.

The future direction of research on CAS No. 91271-79-3, or more accurately referred to as 1-{4-[((pyrrolidin-l -yI) methyl) phenyI}mcthanarnine, will likely focus on refining its pharmacological profile and exploring new applications. Collaborative efforts between academic researchers and industry scientists will be crucial in translating laboratory findings into tangible medical breakthroughs.

In conclusion, 1-{4-[((pyrrolidin-l -yI) methyl) phenyI}mcthanarnine represents an exciting opportunity in pharmaceutical chemistry due to its unique structural features and potential biological activities. The ongoing research efforts aimed at understanding its properties and developing new derivatives hold promise for advancing therapeutic strategies across multiple disease areas.

• 29897-82-3(1-Benzylpyrrolidine)
• 884507-46-4(Benzenemethanamine,N-methyl-3-(1-pyrrolidinylmethyl)-)
• 54225-72-8(Benzenemethanaminium,N,N,N-tributyl-)
• 22014-90-0(Benzenemethanamine,N-butyl-N-(phenylmethyl)-)
• 13048-89-0(1,4-Butanediaminium,N1,N1,N4,N4-tetramethyl-N1,N4-bis(phenylmethyl)-, bromide (1:2))
• 827326-53-4(1-Pyrrolidineethanamine,N-[(3-methylphenyl)methyl]-)
• 221196-25-4(N-BENZYL-N-METHYLPUTRESCINE)
• 4383-27-1(Benzenemethanamine, N,N-dibutyl-)
• 91271-78-2(3-(Pyrrolidin-1-ylmethyl)phenylmethanamine)
• 63885-00-7(Pyrrolidinium,1,1'-[1,4-phenylenebis(methylene)]bis[1-methyl-, dibromide (9CI))